TargetMol

Crizotinib Interm 7654

Product Code:
 
TAR-T31097
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T31097-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Crizotinib Interm 7654?is an important intermediate for the synthesis of pharmaceutical compounds.
CAS:
877397-65-4
Formula:
C8H7Cl2FO
Molecular Weight:
209.04
Purity:
0.98
SMILES:
CC(C1=C(C=CC(=C1Cl)F)Cl)O

References

1. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Moss? YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. PubMed PMID: 25517749; PubMed Central PMCID: PMC4269829. 2. Clegg IM, Daly AM, Donnelly C, Hardy R, Harris D, Jackman H, Jones R, Luan A, ?McAndrew D, McGauley P, Pearce J, Scotney G, Yeow ML. Application of mid-infrared spectroscopy to the development and transfer of a manufacturing process for an active pharmaceutical ingredient. Appl Spectrosc. 2012 May;66(5):574-9. doi: 10.1366/11-06380. PubMed PMID: 22524963. 3. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18. PubMed PMID: 21502504; PubMed Central ?PMCID: PMC3088626.